[go: up one dir, main page]

WO2008113970A3 - Peptides - Google Patents

Peptides Download PDF

Info

Publication number
WO2008113970A3
WO2008113970A3 PCT/GB2008/000732 GB2008000732W WO2008113970A3 WO 2008113970 A3 WO2008113970 A3 WO 2008113970A3 GB 2008000732 W GB2008000732 W GB 2008000732W WO 2008113970 A3 WO2008113970 A3 WO 2008113970A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
epitope
seq
peptide
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/000732
Other languages
French (fr)
Other versions
WO2008113970A2 (en
Inventor
Shahriar Behboudi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0705115A external-priority patent/GB0705115D0/en
Priority claimed from GB0705251A external-priority patent/GB0705251D0/en
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of WO2008113970A2 publication Critical patent/WO2008113970A2/en
Publication of WO2008113970A3 publication Critical patent/WO2008113970A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to peptides comprising a fragment of the human alpha- fetoprotein molecule of SEQ ID NO: 1, wherein said peptides comprise: (a) amino acids 46-55 of SEQ ID NO: 1; (b) a variant of (a) in which one, two or three amino acids are deleted; or (c) a variant of (a) comprising one, two, three or four amino acid substitutions from the sequence of (a); wherein said peptide is capable of activating T cells that produce TGF-β and/or GM-CSF, and wherein said peptide does not comprise a B cell epitope, a CTL epitope or a ThI epitope.
PCT/GB2008/000732 2007-03-16 2008-03-05 Peptides Ceased WO2008113970A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0705115A GB0705115D0 (en) 2007-03-16 2007-03-16 Peptides
GB0705115.4 2007-03-16
GB0705251.7 2007-03-19
GB0705251A GB0705251D0 (en) 2007-03-19 2007-03-19 Peptides

Publications (2)

Publication Number Publication Date
WO2008113970A2 WO2008113970A2 (en) 2008-09-25
WO2008113970A3 true WO2008113970A3 (en) 2008-12-24

Family

ID=39637614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000732 Ceased WO2008113970A2 (en) 2007-03-16 2008-03-05 Peptides

Country Status (1)

Country Link
WO (1) WO2008113970A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN116970061A (en) 2016-12-22 2023-10-31 库尔生物制药有限公司 T cell modulating multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
PH12019502076A1 (en) 2017-03-15 2020-10-26 Cue Biopharma Inc Methods for modulating an immune response
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
WO2020132135A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN116096405A (en) 2020-05-12 2023-05-09 Cue生物制药股份有限公司 Multimeric T cell regulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022787A1 (en) * 1995-01-24 1996-08-01 Murgita Robert A Recombinant human alpha-fetoprotein and uses thereof
WO2001058922A2 (en) * 2000-02-10 2001-08-16 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022787A1 (en) * 1995-01-24 1996-08-01 Murgita Robert A Recombinant human alpha-fetoprotein and uses thereof
WO2001058922A2 (en) * 2000-02-10 2001-08-16 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALISA AKEEL ET AL: "Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 11, no. 18, 15 September 2005 (2005-09-15), pages 6686 - 6694, XP002476998, ISSN: 1078-0432 *
ALISA AKEEL ET AL: "Human CD4(+) T cells recognize an epitope within alpha-fetoprotein sequence and develop into TGF-beta-producing CD4(+) T cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 APR 2008, vol. 180, no. 7, 1 April 2008 (2008-04-01), pages 5109 - 5117, XP002491840, ISSN: 0022-1767 *
AYARU LAKSHMANA ET AL: "Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 178, no. 3, 1 February 2007 (2007-02-01), pages 1914 - 1922, XP002476999, ISSN: 0022-1767 *
LIU YANG ET AL: "Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JUL 2006, vol. 177, no. 1, 1 July 2006 (2006-07-01), pages 712 - 721, XP002491839, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2008113970A2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2008113970A3 (en) Peptides
EP2594582A3 (en) Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens
MX2011011960A (en) Cell membrane-permeable peptides.
RU2016146198A (en) THERAPEUTIC DLL4-BINDING PROTEINS
UA110599C2 (en) Peptide for Immunotherapy of Tumors, Including Neuronal Tumors and Tumors of the Brain
IN2012DN02981A (en)
IN2014CN02050A (en)
NZ600731A (en) Oxyntomodulin peptide analogue
WO2005115306A3 (en) Keratin-binding polypeptides
EP2476698A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
WO2007076162A3 (en) Antimicrobial cathelicidin peptides
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
NZ600363A (en) Modified porcine somatotropin polypeptides and their uses
WO2008113536A8 (en) Neurotrophic peptides
WO2011135222A3 (en) Use of peptides as transporters intended for the internalization of molecules of interest into target cells
EP2481748A3 (en) Foxp3 peptide vaccine
JP2008521795A5 (en)
CY1111630T1 (en) CYCLING PRODUCERS
WO2006046239A3 (en) A thymus-specific protein
NZ603611A (en) Insulin-like growth factor 1 receptor binding peptides
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
NZ591133A (en) Novel melanoma antigen peptide and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08709589

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08709589

Country of ref document: EP

Kind code of ref document: A2